Roche has secured the US Food and Drug Administration (FDA) approval for its Anti-Müllerian hormone (AMH) assay to assist women planning for pregnancy and address infertility in women.

The Elecsys AMH blood test is a simple blood test which measures serum AMH, which is used for the clinical assessment of ovarian reserve.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

AMH is produced by granulosa cells of ovarian follicles during its early stages of development.

AMH concentrations tend to gradually decrease with an advancing age until it becomes undetectable before menopause following an initial increase till early adulthood in a woman.

Individual AMH serum concentration gives an accurate information on the size of the pool of antral follicles, representing the quantity of the remaining primordial follicles.

Unlike the assessment of ovarian reserve using vaginal ultrasound, the AMH blood test generates results independent of the operator or the clinic.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The assay can be used on all Roche immunoassay systems for low, mid- and high-volume testing environments, including the cobas e 411, cobas e 601, cobas e 602 and MODULAR ANALYTICS E170 analyzers.

"Individual AMH serum concentration gives an accurate information on the size of the pool of antral follicles, representing the quantity of the remaining primordial follicles."

Roche Diagnostics chief medical officer Dr Alan Wright said: "Our new assay will help more doctors incorporate AMH testing into their routine clinical practice, ensuring that more women who have questions about their fertility can get answers, faster.

"With over 7.4 million women in the US who have ever used fertility services and one in eight couples having trouble getting or sustaining pregnancy, the need for a consistent, reproducible and robust fertility measurement for women has never been greater."

Currently, Roche offers a range of fertility assays that process in 18 minutes enabling a quick evaluation of patients.

Image: Roche Diagnostics North American headquarters. Photo: courtesy of Roche Diagnostics Corporation.